Express Scripts kicks another batch of meds off its preferred formulary

Vocal pharma-pricing critic Express Scripts ($ESRX) added almost 20 products to its list of excluded meds for 2016. With 80 drugs now ineligible for routine reimbursement, the pharmacy benefits manager says it has excluded about $1.3 billion worth of costs. The new National Preferred Formulary can apply to up to 25 million members. Report

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.